In vitro and in vivo characterization of a new enterovirus type 71-specific human intravenous immunoglobulin manufactured from selected plasma donors

Journal of Clinical Virology

Volumn 51, Issue 4, 2011, Pages 246-249

  Cao, Rui Yuan ^a   Han, Jian Feng ^a   Jiang, Tao ^a   Tian, Xue ^a   Yu, Man ^a   Deng, Yong Qiang ^a   Qin, E De ^a   Qin, Cheng Feng ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Enterovirus 71; Hand, foot and mouth disease; Intravenous immunoglobulin; Neutralization antibody

Indexed keywords

ANTIENTEROVIRUS 71 NEUTRALIZING ANTIBODY; HUMAN IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD DONOR; CHINESE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; ENTEROVIRUS 71; ENTEROVIRUS 71 INFECTION; ENTEROVIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; SURVIVAL TIME;

EID: 79960070423     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.05.002     Document Type: Article

References (31)

1. Schmidt N.J., Lennette E.H., Ho H.H. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 1974, 129:304-309.
2. Mcminn P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 2002, 26:91-107.
3. Solomon T., Lewthwaite P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010, 10:778-790.
4. Bayry J., Lacroix-Desmazes S., Kazatchkine M.D., Kaveri S.V. Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?. Trends Pharmacol Sci 2004, 25:306-310.
5. Casadevall A., Dadachova E., Pirofski L. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004, 2:695-703.
6. Ben-Nathan D., Gershoni-Yahalom O., Samina I., Khinich Y., Nur I., Laub O., et al. Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC Infect Dis 2009, 9:18.
7. Goldsmith J.C., Eller N., Mikolajczyk M., Manischewitz J., Golding H., Scott D.E. Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia. Vox Sang 2004, 86:125-129.
8. Farcet M.R., Planitzer C.B., Stein O., Modrof J., Kreil T.R. Hepatitis A virus antibodies in immunoglobulin preparations. J Allergy Clin Immunol 2010, 125:198-202.
9. Cao R., Han J., Deng Y., Yu M., Qin E., Qin C. Presence of high titer neutralization antibodies against enterovirus 71 in intravenous immunoglobulin manufactured from Chinese donors. Clin Infect Dis 2010, 50:125-126.
10. Planitzer C.B., Modrof J., Kreil T. West Nile virus neutralization by US plasma-derived immunoglobulin products. J Infect Dis 2007, 196:435-440.
11. Chang L.Y., Tsao K.C., Hsia S.H., Shih S.R., Huang C.G., Chang W.K., et al. Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA 2004, 291:222-227.
12. Zhang Y., Tan X.J., Wang H.Y., Yan D.M., Zhu S.L., Wang D.Y., et al. An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J Clin Virol 2009, 44:262-267.
13. Mao L.X., Wu B., Bao W.X., Han F.A., Xu L., Ge Q.J., et al. Epidemiology of hand, foot, and mouth disease and genotype characterization of Enterovirus 71 in Jiangsu, China. J Clin Virol 2010, 49:100-104.
14. Yang F., Ren L., Xiong Z., Li J., Xiao Y., Zhao R., et al. Enterovirus 71 outbreak in P.R. China, 2008. J Clin Microbiol 2009, 13:2351-2352.
15. Ong K.C., Devi S., Cardosa M.J., Wong K.T. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol 2010, 84:661-665.
16. Reed L.J., Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938, 27:493-497.
17. Bible J.M., Iturriza-Gomara M., Megson B., Brown D., Pantelidis P., Earl P., et al. Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. J Clin Microbiol 2008, 46:3192-3200.
18. Barbani M.T., Gorgievski-Hrisoho M. Rapid detection of respiratory picornaviruses in nasopharyngeal aspirates by immunofluorescence assay. J Clin Virol 2009, 45:245-248.
19. Trallero G., Avellon A., Otero A., De Miguel T., Perez C., Rabella N., et al. Enteroviruses in Spain over the decade 1998-2007: virological and epidemiological studies. J Clin Virol 2010, 47:170-176.
20. Lee M.S., Chang L.Y. Development of enterovirus 71 vaccines. Expert Rev Vaccines 2010, 9:149-156.
21. Chen T.C., Chang H.Y., Lin P.F., Chern J.H., Hsu J.T., Chang C.Y., et al. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. Antimicrob Agents Chemother 2009, 53:2740-2747.
22. Luo S.T., Chang P.S., Chao A.S., Liou G.Y., Lin R., Lin T.Y., et al. Enterovirus 71 maternal antibodies in infants, Taiwan. Emerg Infect Dis 2009, 15:581-584.
23. Diedrich S., Weinbrecht A., Schreier E. Seroprevalence and molecular epidemiology of enterovirus 71 in Germany. Arch Virol 2009, 154:1139-1142.
24. Keller M.A., Stiehm E.R. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000, 13:602-614.
25. Wang S.M., Ho T.S., Shen C.F., Liu C.C. Enterovirus 71, one virus and many stories. Pediatr Neonatol 2008, 49:113-115.
26. Wang S.M., Lei H.Y., Huang M.C., Su L.Y., Lin H.C., Yu C.K., et al. Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. J Clin Virol 2006, 37:47-52.
27. McMinn P., Stratov I., Nagarajan L., Davis S. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis 2001, 32:236-242.
28. Bayry J., Lacroix-Desmazes S., Kazatchine M.D., Kaveri S.V. Intravenous immunoglobulin for infectious diseases: tailor-made or universal?. J Infect Dis 2003, 188:1610-1611.
29. Chang L.Y., Hsiung C.A., Lu C.Y., Lin T.Y., Huang F.Y., Lai Y.H., et al. Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Peidatr Res 2006, 60:466-471.
30. Lin T.Y., Hsia S.H., Huang Y.C., Wu C.T., Chang L.Y. Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin Infect Dis 2003, 36:269-274.
31. Wang S.M., Lei H.Y., Huang K.J., Wu J.M., Wang J.R., Yu C.K., et al. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: role of cytolines and cellular immune activation in patients with pulmonary edema. J Infect Dis 2003, 188:564-570.